A securities class action has been filed in the USDC – MN. against Inspire Medical Systems, Inc. (INSP) (“Inspire” or the “Company”), on behalf of all persons and entities that purchased or otherwise acquired Inspire common stock between August 6, 2024, and August 4, 2025, both dates inclusive (the “Class Period”).
Inspire develops and manufactures an implantable medical device for the treatment of obstructive sleep apnea eponymously called “Inspire.” The most recent iteration of the device, Inspire V, uses an implanted sensor and neurostimulator that, according to the Company, are designed to improve respiration during sleep. Defendants touted Inspire V as groundbreaking, with the potential to drive revenue growth in an increasingly competitive market. Accordingly, investors were laser focused on the development and roll-out of this critical product.
The Complaint alleges that throughout the Class Period, Defendants misrepresented and failed to disclose key facts about Inspire V, including the actual market demand for the device and whether the company had taken the steps necessary to successfully launch it. Defendants issued a series of materially false and misleading statements that led investors to believe demand for Inspire V was strong and that Company had taken the necessary steps for a successful launch.
The Company’s common stock declined $42.04 per share, or more than 32%, from a close of $129.95 per share on August 4, 2025, to close at $87.91 per share on August 5, 2025, wiping out $1.2 billion in market capitalization in a single day of trading.
If you purchased Inspire common stock during the Class Period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.